Core Viewpoint - Yaojie Ankang (Nanjing) Technology Co., Ltd. has become a "meme stock" in the Hong Kong market, experiencing significant volatility in its stock price and market capitalization [2][3]. Stock Performance - After several days of continuous gains, Yaojie Ankang's stock surged by 49% in the morning session, reaching a market capitalization of HKD 246 billion. However, it later plummeted by over 20%, resulting in a current stock price of HKD 324.6 and a market cap of HKD 128.8 billion [3]. - The company has lost over HKD 100 billion in market value in less than six months [4]. Company Announcements - Yaojie Ankang announced that it is unaware of any reasons for the recent abnormal fluctuations in stock price and trading volume. The board confirmed that there is no significant change in the company's business operations or financial status [4][5]. Financial Performance - For the first half of 2025, Yaojie Ankang reported a net loss of RMB 123 million, compared to a loss of RMB 160 million in the same period last year. The company continues to have no revenue [6][8]. - Research and development expenses for the first half of 2025 amounted to RMB 98.43 million, while management expenses were RMB 27.47 million [8]. Assets and Liabilities - As of June 30, 2025, Yaojie Ankang held cash and cash equivalents of RMB 449.07 million and total equity of RMB 582.2 million [9]. Clinical Trials - The company received clinical approval for its core product, Tinengotinib (TT-00420), for a Phase II trial in treating hormone receptor-positive and HER2-negative metastatic breast cancer on September 10, 2025 [10].
药捷安康先拉升又大跌：一天市值蒸发超千亿 无收入，已成妖股
Sou Hu Cai Jing·2025-09-16 08:43